Benign elevations in serum aminotransferases and biomarkers of hepatotoxicity in healthy volunteers treated with cholestyramine

Table 1 Classical clinical chemistry parameters following cholestyramine administration in placebo- or moxifloxacin-treated subjects

Subject#	Treatment type	ALT (U/L) baseline	ALT (U/L) peak	Peak ALT(ULN)	AST (ULN)	ALP (ULN)	Total bilirubin (ULN)
1	Placebo	16	273	6.1	1.8	1.0	0.6
2	Placebo	19	320	9.4	3.6	0.7	0.4
3	Placebo	15	967	28.4	10.9	0.9	0.6
4	Placebo	18	119	3.5	1.9	0.7	0.5
5	Placebo	16	145	4.3	2.6	0.6	0.8
6	Placebo	12	146	4.3	2.6	0.6	0.4
7	Moxifloxacin	33	164	3.6	1.8	1.1	0.3
8	Moxifloxacin	32	173	3.8	2.0	0.6	0.5
9	Moxifloxacin	30	229	5.1	2.7	1.4	0.9
10	Moxifloxacin	14	142	3.2	1.5	0.7	0.9
11	Moxifloxacin	20	136	4.0	1.9	0.8	0.4

For ALT, both absolute peak value and ULN have been included. For AST, ALP, and total Bilirubin only ULN have been included.